Teva Reports Strong Second Quarter 2015 Results and Raises Guidance for Full-Year 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
JPMorgan Reinstates Teva Pharma (TEVA) at Overweight
August 3, 2015 8:40 AM EDTJPMorgan reinstated coverage on Teva Pharma (NYSE: TEVA) with an Overweight rating and a price target of $82.00 (prior $70.00).
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $69.02 yesterday.
... MoreTeva Pharma (TEVA) Tops Q2 EPS by 12c; Boosts FY15 EPS Outlook
July 30, 2015 7:06 AM EDTTeva Pharma (NYSE: TEVA) reported Q2 EPS of $1.43, $0.12 better than the analyst estimate of $1.31. Revenue for the quarter came in at $4.97 billion versus the consensus estimate of $4.9 billion.
Teva Pharma sees FY2015 EPS of $5.15-$5.40, versus prior guidance of $5.05-$5.35 and the consensus of... More
